The $20 million non-dilutive funding and strong cash position reduce near-term financing risk and support execution through the CATT1 topline readout. Traders should monitor enrollment completion in Q3 2026 and any updates on trial progress as key catalysts. However, the widening losses and lack of revenue may pressure sentiment if clinical milestones are delayed.
Price Chart
Executive Summary
vTv Therapeutics reported Q4 and full-year 2025 financial results, highlighted by a significant cash increase to $88.9 million from an $80 million financing and a $20 million upfront payment from Newsoara under an amended licensing deal. The company expects to complete enrollment in its Phase 3 CATT1 trial for cadisegliatin in Q3 2026, with a funding runway extending beyond the topline readout. However, net losses widened year-over-year due to higher R&D and G&A expenses.
Key Financial Metrics
Key Facts
- Received $20.0 million upfront from Newsoara in February 2026 under an amended licensing agreement for global rights to PDE4 inhibitor HPP737.
- Cash position was $88.9 million as of December 31, 2025, up from $36.7 million a year prior, driven by $80 million private placement and licensing proceeds.
- Net loss for Q4 2025 was $7.1 million vs. $3.6 million in Q4 2024; full-year 2025 net loss was $27.0 million vs. $18.5 million in 2024.
- R&D expenses increased to $17.9 million in 2025 from $11.5 million in 2024, primarily due to cadisegliatin clinical trials.
- Enrollment in the Phase 3 CATT1 trial is expected to complete in Q3 2026, with topline data to follow.
- No revenue was generated in 2025, compared to $1.0 million in 2024.
Financial Impact
Cash increased by $52.2 million YoY; $20 million non-dilutive licensing inflow in 2026 strengthens near-term liquidity. However, operating losses expanded significantly, with full-year net loss up 46% YoY.
Risk Factors
- Clinical trial delays could push back topline data and increase cash burn.
- Cadisegliatin may fail to demonstrate efficacy or safety in Phase 3, leading to a significant stock decline.
- Future warrant liability fluctuations could create additional non-cash volatility in earnings.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253292 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 10, 2026 16w ago | DEFA14A | $31.59 $33.35 | ▲ +5.57% | ▲ +1.18% | $31.36 (−0.73%) |
May 8, 2026 20w ago | Press Release | $30.46 $34.39 | ▲ +12.90% | ▲ +8.51% | $31.36 (+2.95%) |
Mar 10, 2026 29w ago | Press Release | $35.10 $32.94 | ▼ −6.15% | ▼ −17.68% | $31.36 (−10.66%) |
Feb 26, 2026 31w ago | 8-K | $39.32 $35.50 | ▼ −9.72% | ▼ −17.47% | $31.36 (−20.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access